Long-term efficacy of lebrikizumab in treating head, neck and face involvement in patients with moderate-to-severe atopic dermatitis

Head, neck, and face (HNF) atopic dermatitis (AD) substantially impairs quality of life, yet long-term biologic efficacy data in HNF areas remain limited.

This post hoc analysis evaluates HNF efficacy of lebrikizumab across phase 3 trials (ADvocate 1&2, ADjoin) and targeted populations (ADmirable, ADapt) in adolescents (≥12 years, ≥40 kg) and adults with moderate-to-severe AD. Outcomes included HN EASI sub-scores and Face Investigator's Global Assessment (F-IGA).